MIR452 and acute kidney injury: Although NephroCheck – the only FDA-approved AKI detection test – relies on urinary [TIMP2-IGFBP7], urinary MIR452 shows higher sensitivity (87.23% vs. 61.54%) albeit slightly lower specificity (78.00% vs. 87.18%) [164].